Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Barrett's esophagus: progression to adenocarcinoma and markers 10th World Congress of the World Organization for Specialized Studies on Diseases of the Esophagus (OESO) Fang, D., Das, K. M., Cao, W., Malhotra, U., Triadafilopoulos, G., Najarian, R. M., Hardie, L. J., Lightdale, C. J., Beales, I. L., Felix, V. N., Schneider, P. M., Bellizzi, A. M. BLACKWELL SCIENCE PUBL. 2011: 210–229

Abstract

The following on progression to adenocarcinoma and markers of Barrett's esophagus includes commentariess on the expression of claudin 4 in Barrett's adenocarcinoma; the role of acid and bile salts; the role of insulin-like growth factor; the value of reactive oxygen species; the importance of abnormal methylation; genetic alterations in stromal cells and genomic changes in the epithelial cells; the value of confocal laser endomicroscopy for the subsurface analysis of the mucosa; indications for statins as adjuvant chemotherapeutic agent; the sequence of molecular events in malignant progression in Barrett's mucosa; and the value of the macroscopic markers and of p53 mutations.

View details for DOI 10.1111/j.1749-6632.2011.06053.x

View details for Web of Science ID 000301188400013

View details for PubMedID 21950815